IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC | Intellectia.AI
IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC
Written by Emily J. Thompson, Senior Investment Analyst
Clinical Trial Presentation: IDEAYA Biosciences and Jiangsu Hengrui Pharmaceuticals will present clinical efficacy and safety data from a Phase 1 trial of IDE849 in small-cell lung cancer (SCLC) patients at the IASLC 2025 World Conference on Lung Cancer, highlighting its potential as a first-in-class DLL3-targeting antibody drug conjugate.
Combination Therapy Exploration: The conference will also feature a poster presentation on the combination of TOP1-payload based ADCs with IDE161, a PARG inhibitor, aiming to enhance treatment durability for cancer patients.
IDYA
$33.81+Infinity%1D
Analyst Views on IDYA
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 50.81 USD with a low forecast of 30.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
18 Analyst Rating
Wall Street analysts forecast IDYA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IDYA is 50.81 USD with a low forecast of 30.00 USD and a high forecast of 90.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Buy
2 Hold
0 Sell
Strong Buy
Current: 33.370
Low
30.00
Averages
50.81
High
90.00
Current: 33.370
Low
30.00
Averages
50.81
High
90.00
Citi
Buy
maintain
$64
2025-12-12
New
Reason
Citi
Price Target
$64
2025-12-12
New
maintain
Buy
Reason
Citi placed an "upside 90-day catalyst watch" on Ideaya Biosciences while keeping a Buy rating on the shares with a $64 price target. The firm likes the share setup into the Phase 2/3 OptimUM-02 trial data, expected in Q1, for metastatic uveal melanoma.
Truist
Buy
initiated
$59
2025-11-24
Reason
Truist
Price Target
$59
2025-11-24
initiated
Buy
Reason
Truist initiated coverage of Ideaya Biosciences with a Buy rating and $59 price target. The company's lead asset, darovasertib/PKCi has a major valuation inflection point approaching from the phase II/III MUM's PFS topline readout that could support accelerated approval, the analyst tells investors in a research note. Based on strong phase II data and positive feedback from key opinion leaders, Truist sees favorable reward-risk profile for the upcoming phase II/III PFS topline readout with roughly 85% probability.
Mizuho
Graig Suvannavejh
Outperform
maintain
$44 -> $46
2025-11-11
Reason
Mizuho
Graig Suvannavejh
Price Target
$44 -> $46
2025-11-11
maintain
Outperform
Reason
Mizuho analyst Graig Suvannavejh raised the firm's price target on Ideaya Biosciences to $46 from $44 and keeps an Outperform rating on the shares. The firm updated the company's model post the Q3 report.
JPMorgan
Overweight
maintain
$74 -> $79
2025-10-23
Reason
JPMorgan
Price Target
$74 -> $79
2025-10-23
maintain
Overweight
Reason
JPMorgan raised the firm's price target on Ideaya Biosciences to $79 from $74 and keeps an Overweight rating on the shares. The firm cites an increased probability of success for darovasertib in the neoadjuvant setting, to 70% from 60%, for the target bump. It estimates peak sales of darovasertib to be $500M in the U.S. alone. JPMorgan sees share upside for Ideaya into the metastatic uveal melanoma update.
About IDYA
IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 / GSK959 (Werner Helicase), IDE161 (PARG), and IDE705 / GSK101 (Pol Theta Helicase). IDE196, a small-molecule protein kinase C (PKC) inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397 is its small-molecule methionine adenosyltransferase 2a (MAT2A) inhibitor. IDE275 (GSK959) Werner Helicase (WRN) inhibitor for patients having tumors with MSI-High. IDE161 (PARG) is a small-molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor. IDE705 is a small-molecule inhibitor of Pol Theta Helicase, in combination with niraparib, the GSK small-molecule inhibitor of poly-(ADP-ribose) polymerase (PARP).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
